Skip to main content
. 2014 Mar 4;7(2):188–195. doi: 10.1016/j.tranon.2014.02.003

Figure 4.

Figure 4

Combination studies of trebananib, L1-7, and mL4-3 with sunitinib on RCC xenograft tumor growth and perfusion. (A) Both trebananib and L1-7 improved the activity of sunitinib to a similar extent. mL4-3 did not improve sunitinib activity. (B) Representative ASL MRI perfusion images show tumor perfusion results at baseline (pretreatment), 1 week, 3 weeks, and 7 weeks after treatment with sunitinib + Fc, sunitinib + mL4-3, sunitinib + L1-7, and sunitinib + trebananib. Combination treatment of sunitinib and L1-7 or trebananib prevented or delayed the resumption of tumor perfusion compared to sunitinib + Fc treatment. Trebananib and L1-7 had similar effects on tumor perfusion reduction and prevention of tumor perfusion resumption with sunitinib treatment alone. Tumor regions are outlined in red in ASL perfusion images (right column of each time point) and the corresponding reference proton density images (left column). The tumor size (in mm) and mean blood flow (in ml/100 g per min) are shown below each image. The color bar beside the images represents the range of perfusion values from 0 to 160 ml/100 g per min. (C) Bar graph demonstrating the quantification of ASL MRI tumor perfusion at the time of resistance to sunitinib (~ day 50 after treatment). The combination of sunitinib and either trebananib or L1-7 prevented the restoration of tumor perfusion observed with sunitinib alone at the time of resistance (**P < 0.001).